Loading stock data…
$673.82-2.72 (-0.40%)
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. in the Healthcare sector is trading at $673.82 with a market capitalization of $232.5B. Wall Street consensus targets $750.92 (25 analysts), implying a +11.4% move over the next 12 months. The stock is currently near its 52-week high of $705.79, remaining 22.8% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $11.99B↑ | $11.01B↓ | $12.21B↑ | $11.12B↑ | $10.85B |
| Gross Profit | $4.88B↑ | $4.43B↓ | $5.01B↑ | $4.58B↑ | $4.41B |
| Operating Income | $2.19B↑ | $1.91B↓ | $2.30B↑ | $2.08B↑ | $1.92B |
| Net Income | $1.74B↑ | $1.65B↓ | $1.96B↑ | $1.62B | $1.62B |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Inst...
Academic risk and quality models computed from TMO's own filings and price history, not from analyst opinion.
Mixed: 5 of 9 fundamental-health tests pass, so profitability and balance-sheet trends disagree.
Altman Z above the 2.99 safe threshold, so the model puts bankruptcy risk in its lowest band.
Beneish M below the -1.78 flag threshold, so the earnings-manipulation model finds nothing unusual in the accruals and margin trends.
Share of earnings coming from accruals rather than cash. Higher values historically precede weaker future returns.
Hidden Markov model fitted to two years of returns, separating bull, bear and sideways states by their own drift and volatility.
GARCH(1,1) 30-day annualised forecast, below the current 33.7% reading.
Fama-French 5-factor market beta. The five factors explain 16% of this stock's return variance; the rest is idiosyncratic.
The stock’s own historical valuation anchor, which is a fairer comparison than a sector average for a company with a persistent premium or discount.
Model inputs as of 2026-10-23.